Stockscreener 앱 받기
1.65
3.12%
0.05
시간 외 거래:
1.65
전일 마감가:
$1.60
열려 있는:
$1.6
하루 거래량:
247.39K
Relative Volume:
0.53
시가총액:
$36.08M
수익:
$752.00K
순이익/손실:
$-68.21M
주가수익비율:
-0.1701
EPS:
-9.6977
순현금흐름:
$-58.21M
1주 성능:
-0.60%
1개월 성능:
+10.74%
6개월 성능:
-53.78%
1년 성능:
-38.89%
1일 변동 폭
$1.5745
$1.68
1주일 범위
$1.54
$1.79
52주 변동 폭
$1.17
$8.08
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.65 | 34.99M | 752.00K | -68.21M | -58.21M | -9.6977 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-06 | 재확인 | BofA Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-30 | 개시 | Goldman | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-04 | 개시 | Guggenheim | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
BTAI PE Ratio & Valuation, Is BTAI Overvalued - Intellectia AI
BTAI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AI Drugmaker BioXcel Eyes $9.8M Investor Settlement - Law360
BTAI SEC FilingsBioxcel Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BioXcel Submits sNDA for Igalmi to Treat Agitation - Intellectia AI
Is BioXcel Therapeutics Inc. stock good for income investorsJuly 2025 Rallies & Risk Controlled Stock Alerts - mfd.ru
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia - Bitget
BioXcel Therapeutics (BTAI) Hosts Roundtable on Acute Agitation in Alzheimer's - GuruFocus
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia - The Manila Times
Doctors tackle 100M Alzheimer’s agitation episodes in new BioXcel webcast - Stock Titan
Why BioXcel Therapeutics Inc. stock is favored by pension fundsJuly 2025 Macro Moves & Advanced Technical Analysis Signals - mfd.ru
Aug Weekly: Is BioXcel Therapeutics Inc gaining market shareTrade Exit Report & Safe Swing Trade Setups - baoquankhu1.vn
BioXcel Therapeutics Reports Successful Primary Endpoint Achievement in SERENITY At-Home Phase 3 Safety Trial, Supporting sNDA for IGALMI® Label Expansion - Intellectia AI
Can BioXcel Therapeutics Inc. stock hit record highs againBond Market & Weekly Breakout Opportunity Watchlist - mfd.ru
BTAI Should I Buy - Intellectia AI
What earnings margins imply for BioXcel Therapeutics Inc. (BX20) stockJuly 2025 Levels & Daily Momentum Trading Reports - mfd.ru
Movement Recap: Is BioXcel Therapeutics Inc. benefiting from interest rate changes2025 Top Decliners & AI Driven Stock Movement Reports - mfd.ru
Bioxcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for Igalmi in the At-Home Setting - marketscreener.com
BioXcel Therapeutics (BTAI) Advances with Igalmi for At-Home Use - GuruFocus
BioXcel Highlights IGALMI At-Home Acute Agitation Opportunity - TipRanks
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting - The Manila Times
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI in the At-Home Setting - Bitget
BioXcel Therapeutics Completes Market Assessment for IGALMI - TradingView
BioXcel Therapeutics Completes Market Opportunity - GlobeNewswire
How cyclical is BioXcel Therapeutics Inc.’s revenue streamPortfolio Gains Report & High Accuracy Buy Signal Tips - mfd.ru
Aug Selloffs: What are the risks of holding BioXcel Therapeutics Inc.Weekly Volume Report & Consistent Growth Stock Picks - mfd.ru
Is BioXcel Therapeutics Inc.’s growth already priced inWeekly Gains Summary & Weekly Watchlist for Hot Stocks - mfd.ru
BioXcel Therapeutics announces milestone and retention bonuses for key executives - Investing.com
BioXcel sets milestone bonuses amid pivotal IGALMI review - TipRanks
CEO Moves: What is GMFIWs 5 year growth outlookTrade Entry Report & Community Supported Trade Ideas - baoquankhu1.vn
Rate Hike: Is BioXcel Therapeutics Inc gaining market share2025 Key Highlights & Growth Focused Entry Reports - baoquankhu1.vn
Movement Recap: Is BioXcel Therapeutics Inc. stock a falling knife or bargain buyJuly 2025 Opening Moves & Stepwise Trade Signal Guides - mfd.ru
BioXcel Says Doctor Sent Fake Email About Alzheimer's Trial - Law360
BioXcel Therapeutics submits sNDA for at-home use of IGALMI By Investing.com - Investing.com South Africa
BioXcel seeks FDA approval for at-home IGALMI use - The Globe and Mail
BioXcel Therapeutics (BTAI) Advances Igalmi's Reach with FDA Sub - GuruFocus
BioXcel Therapeutics submits application to expand IGALMI use for at-home treatment - Investing.com Nigeria
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting - The Manila Times
BioXcel Therapeutics Submits Supplemental NDA To US FDA For IGALMI® At-Home Label Expansion - TradingView
BioXcel Therapeutics submits sNDA for at-home use of IGALMI - Investing.com
BioXcel Therapeutics Submits sNDA for IGALMI® At-Home Use - TradingView
What are the risks of holding BioXcel Therapeutics Inc.Weekly Trade Report & Capital Protection Trading Alerts - bollywoodhelpline.com
How BioXcel Therapeutics Inc. (BX20) stock moves on employment data2025 Fundamental Recap & Weekly Breakout Watchlists - bollywoodhelpline.com
Ag Plus, Inc. - Ag Plus, Inc.
Palmetto Grain Brokerage - Palmetto Grain Brokerage
1 Top Penny Stock to Watch Now - Yahoo Finance
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
BioXcel adds chief commercial officer as it prepares to expand agitation drug IGALMI’s reach - Hartford Business Journal
VIX Spike: Can BioXcel Therapeutics Inc. stock maintain growth trajectoryTrade Entry Report & Smart Swing Trading Alerts - Bộ Nội Vụ
BioXcel Therapeutics Appoints Mark Pavao as Interim Chief Commercial Officer - citybiz
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
1.77%
자본화:
|
볼륨(24시간):